The Changing Sensory and Sympathetic Innervation of the Young, Adult and Aging Mouse Femur

Stephane R. Chartier,* Stefanie A. T. Mitchell, Lisa A. Majuta and Patrick W. Mantyh

Department of Pharmacology, University of Arizona, Tucson, AZ 85724, United States
Cancer Center, University of Arizona, Tucson, AZ 85724, United States

Abstract—Although bone is continually being remodeled and ultimately declines with aging, little is known whether similar changes occur in the sensory and sympathetic nerve fibers that innervate bone. Here, immunohistochemistry and confocal microscopy were used to examine changes in the sensory and sympathetic nerve fibers that innervate the young (10 days post-partum), adult (3 months) and aging (24 months) C57Bl/6 mouse femur. In all three ages examined, the periosteum was the most densely innervated bone compartment. With aging, the total number of sensory and sympathetic nerve fibers clearly declines as the cambium layer of the periosteum dramatically thins. Yet even in the aging femur, there remains a dense sensory and sympathetic innervation of the periosteum. In cortical bone, sensory and sympathetic nerve fibers are largely confined to vascularized Haversian canals and while there is no significant decline in the density of sensory fibers, there was a 75% reduction in sympathetic nerve fibers in the aging vs. adult cortical bone. In contrast, in the bone marrow the overall density/unit area of both sensory and sympathetic nerve fibers appeared to remain largely unchanged across the lifespan. The preferential preservation of sensory nerve fibers suggests that even as bone itself undergoes a marked decline with age, the nociceptors that detect injury and signal skeletal pain remain relatively intact.

Key words: skeletal, nociceptors, pediatric, genetic disorders, geriatric.

INTRODUCTION

The study of chronic skeletal pain most commonly focuses on diseases such as osteoarthritis, low back pain and fragility fractures which are due in large part to the age-related decline in the mass, quality and strength of the skeleton (Heaney et al., 2000; Melton et al., 2004; Mantyh, 2014). However, there are over 500 human genetic disorders of bone and cartilage. In many cases, the first symptom that prompts diagnosis of these disorders is chronic skeletal pain in the young neonatal and pediatric patient (McCarthy, 2011; Boyce, 2017). Genetic disorders of bone and joint which are accompanied by significant skeletal pain include; osteogenesis imperfecta (Rauch et al., 2002; Semler et al., 2012; Hoyer-Kuhn et al., 2014, Ward et al., 2016, Boyce, 2017), giant cells tumor (Chawla et al., 2013; Karras et al., 2013, Martin-Broto et al., 2014, Gossai et al., 2015), aneurysmal bone cyst (Lange et al., 2013; Pelle et al., 2014), fibrous dysplasia (Boyce et al., 2012; Naidu et al., 2014), Paget’s disease (Grasemann et al., 2013) and juvenile arthritis (Clinch and Eccleston, 2009, Boyce, 2017).

Given that much of the young skeleton is cartilaginous and the peripheral nervous system is still developing (Brandi and Collin-Osdyob, 2006; Sacchetti et al., 2007), a major question is where in the young skeleton are the nociceptors that drive this pain and do nerves in the young bone have the same organization, distribution and density as sensory and sympathetic nerve fibers in adult bone? Similarly, an interesting but largely unanswered question is whether as the mass, quality and strength of bone and cartilage decline with age (Exton-Smith et al., 1969; Woolf and Pfleger, 2003), do the nerves that innervate the skeleton also undergo a marked decline?

One issue that has greatly hindered attempts to directly compare the innervation of young, adult and aging skeletons is that whereas young bone generally requires no decalcification prior to tissue sectioning (as it is mostly cartilaginous) both the adult and aging bone are highly calcified and require significant decalcification before tissue sectioning (Hukkanen et al., 1992, Mantyh et al., 2010; Jimenez-Andrade and Mantyh, 2012,
Chartier et al., 2014). Previous studies have suggested that many antibodies that work well in the non-decalcified tissues frequently showed marked loss of immunostaining when subjected to the decalcification process (Arnold, 1988; Shi et al., 1991; Schulze et al., 1997; Hayat, 2002; Mach et al., 2002, Mantyh et al., 2010, Chartier et al., 2014).

To address this problem, in the present study the young mouse femur was used as a positive control, as this skeletal tissue can be processed for immunohistochemistry with or without decalcification and then stained with antibodies raised to a variety of antigens. While many antibodies showed significant loss of signal with decalcification, three antibodies that showed virtually no loss of immunostaining between the non-decalcified and decalcified young femur and which worked very well in the young, adult and aging femur were; calcitonin gene-related peptide (CGRP) which labels thinly or unmyelinated peptidergic sensory nerve fibers (Kruger et al., 1989, Hukkanen et al., 1993, Clinch and Eccleston, 2009), tyrosine hydroxylase (TH) which is expressed by post-ganglionic adrenergic sympathetic nerve fibers (Parfitt, 2006; Manolagas and Parfitt, 2010), and platelet endothelial cell adhesion molecule (PECAM-1 and also known as CD31) which labels the endothelial cells of blood vessels (Chartier et al., 2014).

In light of the above observations, in the present study antibodies to CGRP, TH and CD31 were used to explore age-related changes in sensory nerves, sympathetic nerves and blood vessels in the mouse femur. The femur was chosen as it is the largest load bearing bone in the body. It clearly shows an age-related decline in mass and strength, and fracture of this bone in humans and mice is accompanied by significant pain (Jimenez-Andrade et al., 2007, 2009; Koewler et al., 2007; Freeman et al., 2008, Chartier et al., 2014). The mouse was chosen as it is the most commonly used experimental species in modeling human genetic diseases of bone and cartilage (McCarthy, 2011) as well as in studies of the injured, diseased and aging skeleton (Mantyh, 2014).

**EXPERIMENTAL PROCEDURES**

**Animals**

Experiments were performed with young (n = 30), adult (n = 30) and aging (n = 30) male C57Bl/6J mice (Jackson Laboratories, Bar Harbor, ME) that were 10 days post-partem, 3 months and 24 months of age, respectively. For all qualitative assessments, the number of animals was equal to or greater than 10 and for all quantitative data the “n” was >5. The mice were housed in accordance with the National Institutes of Health guidelines under specific pathogen-free conditions in autoclaved cages maintained at 22 °C with a 12-h alternating light/dark cycle and access to food and water ad libitum. All procedures adhered to the guidelines of the Committee for Research and Ethical Issues of the International Association for the Study of Pain and were approved by the Institutional Animal Care and Use Committee at the University of Arizona (Tucson, AZ, USA).

**Preparation of tissue for immunohistochemistry and histology**

Tissue from young (10 days) mice and adult (3 months) and aging (24 months) mice were euthanized and processed according to previously published protocols (Thompson et al., 2016). Young mice (10 days) were deep-anesthetized with CO2 delivered from a compressed gas cylinder then decapitated. Young hindlimbs were then excised and placed in 4% formaldehyde/12.5% picric acid solution in 0.1 M PBS (pH 6.9 at 4 °C) overnight. Following fixation, young tissue was either placed in PBS (pH 7.4) for 48 h and then cryoprotected in 30% sucrose at 4 °C or the femurs were then placed in decalcified solution for 2 weeks in 0.5 M ethylenediaminetetraacetic acid (EDTA) (PBS, pH 8.0 at 4 °C) and then cryoprotected in 30% sucrose at 4 °C for at least 48 h before sectioning. Thus, half of the young femurs were placed in the same decalcification solution as required for the mineralized adult and aging femurs while the other young femurs were cryo-sectioned without going through the decalcification process (i.e., the control limbs). These controls were performed in order to assess the potential effects that the decalcification process had on immunohistochemical staining of a variety of antibodies.

Adult and aging mice (3 and 24 months, respectively) were deeply anesthetized with ketamine/xylazine (0.01 ml/g, 100 mg/10 kg, s.c.) and perfused intracardially as previously described (Chartier et al., 2014). Similar to young tissue that was placed in the decalcification solution, adult and aging tissue was placed in 4% formaldehyde/12.5% picric acid solution in 0.1 M PBS (pH 6.9 at 4 °C) overnight. Following fixation, the femurs were decalcified for approximately 2 weeks in 0.5 M EDTA (PBS, pH 8.0 at 4 °C). In all cases, the EDTA solution was changed every day and in the adult and aging animals the decalcification was monitored radiographically with a Faxitron MX-20 digital cabinet X-ray system (Faxitron/Biopics, Tucson, AZ, USA). Following total decalcification, each femur was cryoprotected in 30% sucrose at 4 °C for at least 48 h before being sectioned.

Tissue sections of young, adult and aging femurs were cut at either 20 or 60 μm serially and thaw mounted with two sections of bone per gelatin-coated slide. Sections at 20-μm thickness were stained with Safranin O and 60-μm-thick sections were used for immunofluorescence staining.

**Immunohistochemistry and histology**

In the present study, we focused on the distal end of the femur although a similar organization and age-related changes reported here were observed in other parts of the femur. A full protocol of the histology and immunohistochemical techniques used here can be found in a previous publication from our lab (Chartier et al., 2014). Briefly, following sectioning slides were dried at room temperature (RT) for 30 min and then washed in PBS for 3 × 10 min. Next, the slides were blocked with 3% normal donkey serum (Jackson ImmunoResearch, Cat#: 017-11-121; West Grove, PA, USA) in PBS with 0.3% Triton-X 100 (Sigma Chemical Co., Cat#: X100; St.
were then washed 3 and 1:400; Jackson ImmunoResearch). Preparations fluorescent markers (Cy3/Dylight 488/AlexaFluor; 1:600 at RT with secondary antibodies conjugated to nuclei were labeled using 4 body information can be found in Table 1.

The receptor p75 which is low affinity receptor for NGF was labeled with an antibody for sympathetic neurotrophin receptor that binds NGF and the other member of the neurotrophin family was labeled with an anti-mouse, 1:1000, Cat# AF1056; R&D Systems, Minneapolis, MN, USA). The receptor p75 which is low affinity neurotrophin receptor that regulates the survival, development, and function of sensory and sympathetic neurons, was labeled using an antibody from Santa Cruz (Dallas, TX, USA), polyclonal rabbit anti-mouse, 1:1000, Cat# SC-548. The preferential membrane receptor for NGF was labeled with an antibody for tropomyosin-related kinase A (TrkA, polyclonal goat anti-mouse, 1:1000, Cat#: AF1056; R&D Systems, Minneapolis, MN, USA). The receptor p75 which is low affinity neurotrophin receptor that binds NGF and the other members of the neurotrophin family was labeled with an antibody for p75 (polyclonal rabbit anti-mouse, 1:1000, Cat# AB1554; Millipore, Temecula, CA, USA). Additional anti-body information can be found in Table 1.

After primary antibody incubation, preparations were washed 3 × 10 min each in PBS and incubated for 3 h at RT with secondary antibodies conjugated to fluorescent markers (Cy3/DyLight 488/AlexaFluor; 1:600 and 1:400; Jackson ImmunoResearch). Preparations were then washed 3 × 10 min each in PBS. Cellular nuclei were labeled using 4,6-diamidino-2-phenylindole (DAPI) (1:500; Cat#D21490; Invitrogen, Grand Island, NY, USA) followed by an additional 3 × 10 min wash in PBS. Slides for histological and immunofluorescence were dehydrated through an alcohol gradient (2 min each; 70%, 80%, 90%, and 100%), cleared in xylene (2 × 2 min), and cover slipped with di-n-butylphthalate-poly styrene-xylene (Sigma Chemical Co., Cat#06522; St. Louis, MO). Preparations were allowed to dry covered at RT for 12 h before imaging.

**Bright field and laser confocal microscopy**

Bright field images of histologically stained sections were acquired using an Olympus BX51 microscope fitted with an Olympus DP70 digital CCD. Confocal images of CGRP, TH, CD31, TrkA, p75, NGF and DAPI were acquired using an Olympus FV1200 microscope (Olympus Life Sciences, Center Valley, PA, USA) and a 60×/1.42 PlanApo N objective using excitation beams of 488 and 599 nm, and emissions were detected using BA505-540 and BS75-620 emission filters. Nuclear staining (4′,6-diamidino-2-phenylindole [DAPI]) was visualized using an excitation beam of 405 nm and emissions were detected using a BA430-470 emission filter. Sequential acquisition mode was used to reduce bleed-through from fluorophores. The average volume of data that was collected was 211.7 μm × 211.7 μm × 6 0 μm, with each Z-axis slice being 1.0 μm/slice.

**Periosteal thickness**

In order to measure the thickness of the fibrous and cambium layers of the periosteum, images (TIFF format) acquired under the DAPI channel were opened in Fiji (Schindelin et al., 2012). For both the fibrous and cambium layers, three measurements using the “straight” tool, perpendicular to the cortical wall, were taken of the fibrous and cambium layers of the periosteum. The three total measurements were averaged together in Microsoft Excel and data were presented in μm.

**Frequency, innervation and vascularization of Haversian canals**

In order to measure the occurrence of Haversian canals in young, adult and aging femurs, 60-μm-thick sections were used. For each animal analyzed, three 60-μm sections (1 section per slide) were viewed using an Olympus BX51 bright field/fluorescence microscope and an UPlanSapo 10x/0.40 objective. For each section, the cortical bone compartment in the distal end of the femur was analyzed under the DAPI fluorescence filter as this nuclear stain allowed for easy visualization of the unique

---

**Table 1. Table of primary antibodies used for immunological staining**

| Antigen    | Synthetic/Immunogen | Manufacturer, species raised in, monoclonal, catalog and lot number | Dilution used |
|------------|---------------------|-------------------------------------------------------------------|--------------|
| CGRP       | Synthetic rat Tyr-CGRP conjugated to keyhole limpet hemocyanin | Sigma Chemical Co., rabbit, polyclonal, Cat# C8198, Lot# 059K4841 | 1:10,000     |
| TH         | Tyrosine hydroxylase from rat phenochromocytoma denatured with sodium dodecyl sulfate (complete sequence) | Millipore, rabbit, polyclonal, Cat# AB152, Lot# 2066692 | 1:1000       |
| CD31       | 129/Sv mouse-derived endothelioma cell line iEnd.1 | BD Pharmingen, rat, polyclonal, Cat# 550274 | 1:500        |
| NGF        | N-terminus of NGF mature chain of mouse origin | Santa Cruz, rabbit, polyclonal, Cat# SC-548, Lot# J1909 | 1:1000       |
| TrkA       | Mouse myeloma cell line NSO-derived recombinant rat TrkA | R&D Systems, goat, polyclonal, Cat# AF1056, Lot# VFA011411 | 1:1000       |
| p75        | Recombinant mouse NGF Receptor p75 extracellular fragment | Millipore, rabbit, polyclonal, Cat# AB1554, Lot# 2502888 | 1:1000       |
morphology of a Haversian canal. The total number of Haversian canals, regardless of blood vessel or nerve fiber staining, were then tabulated in Excel. Next, the same section was analyzed again using the corresponding fluorescence filter for CD31 blood vessels, CGRP sensory fibers and then TH sympathetic fibers. The total number of Haversian canals that were CD31+ or CD31− were tabulated and compared with those that were either CGRP+ or TH+ or lacked any nerve fiber staining. All data was entered into Microsoft Excel and the formulas within the program were used to calculate the percentages.

Nerve fiber density

For quantification, frozen sections were used, as cross-sectional analysis allowed for the visualization of the anatomy of the bone and articular cartilage (such as the condyles and growth plate), which enabled the observer to locate the same anatomical area when quantifying different animals. For each animal analyzed, at least 3 images were obtained for each of the 3 quantified bone compartments: periosteum, bone marrow and cartilage. Images were acquired at least 100 μm apart in the vertical Z plane (i.e., two sections) to minimize duplication of quantifications. Nerve fibers were manually traced using Fiji (an open-source, analytic software program) and added together for a total nerve fiber length (mm). To measure the surface area (mm²) of each tissue in each region, we analyzed the same tissue sections from which nerve fiber counts were obtained. The nerve fiber density (mm/mm²) of each tissue was divided by the section thickness (0.06 mm) to obtain the volumetric nerve fiber density. The area of bone was measured from the frontal section of the femur and digital images were acquired using an Olympus FV1200 confocal microscope (further described in "Materials and methods").

Qualitative assessment of immunohistochemical staining

To assess the effect of the decalcification process on immunohistochemical staining we examined CGRP, TH, CD31, NGF, TrkA and p75 staining in tissue sections obtained from; non-decalcified young bone and decalcified young, adult and aging bone. Sections were examined under an Olympus FV1200 confocal microscope using a 60x objective, under which it was possible to distinguish individual nerve fibers. The bone marrow and periosteum region of the distal end of the femur was selected for evaluation due to the ease at which nerve fiber structures could be visualized in this compartment (bone marrow) and the density of nerve fibers (periosteum). Two 60x objective fields of the marrow per animal from 5 animals per group were used for evaluation. We used a scale of − to +++ for qualitative assessment of immunohistochemical staining of nerve fibers. The − indicates no detectable signal; + = minimal signal, requires significant increase in laser power to visualize; ++ = average staining signal, requires minimal increase in laser power to visualize; +++ = maximum staining signal, requires no increase in laser power to visualize.

Statistical analysis

All values are expressed as mean ± SEM. Data for the young, adult and aging mice were analyzed using a 2-factor ANOVA, followed by Tukey’s multiple comparison test with adjusted P values. Student’s t-test was used when comparing 2 means. Significance level was set at p ≤ 0.05. All statistical analyses were performed using Prism (GraphPad, La Jolla, CA, USA).

RESULTS

Histologic comparison of femurs from young (10 days), adult (3 months) and aging (24 months) animals

Across the three examined age groups, young (10 days), adult (3 months) and aging (24 months) there were noticeable histologic differences. Histological analysis of the femur using Safranin O, a stain for cartilage (red) and mineralization (blue), revealed that the young bone was still undergoing mineralization as illustrated by the extensive presence of cartilage throughout the distal head (Fig. 1A). Adult and aging femurs had fully mineralized and displayed hallmarks of a mature femur, closure of the growth plate and fully formed trabecular bone (Fig. 1B,C). Additionally, the young bone was approximately 1/4 the size of the adult and aging bone.

Morphologic and neuronal characteristics of the young, adult and aging periosteum

The periosteum can be divided into two distinct regions, the outer fibrous layer and the inner cambium layer. In the present study, we found that in young, adult and aging animals, the thickness of the cambium layer was 56 ± 2, 20 ± 1 and 6 ± 0.25 microns respectively (Fig. 2A–C, respectively). The morphology of the two periosteal layers was confirmed using confocal microscopy and DAPI counterstaining. In addition to the decline in the thickness of the cambium layer with age, we observed a decline in the thickness of the fibrous layer as well between the young and adult periosteum, 76 ± 2 vs. 24 ± 1 microns, respectively. There was no change in fibrous thickness when comparing the adult and aging periosteum, 24 ± 1 vs. 23 ± 2 microns, respectively.

To investigate the sensory and sympathetic innervation of the periosteum, frozen bone sections from young, adult and aging femurs were labeled with fluorescent antibodies raised against primary antibodies for: CGRP, a marker for peptide-rich C-fibers and some A-delta sensory nerve fibers and TH, a marker for sympathetic nerve fibers. Additionally, we looked at the vascularization of this compartment using CD31, a marker for endothelial cells (Fig. 2). Differential interference contrast (DIC) microscopy was used to show the cortical bone and for orientation purposes. Qualitative analysis revealed that the young periosteum had the highest total number of CGRP+ and TH+...
nerve fibers compared to the adult and aging periosteum (Fig. 2A), with the aging periosteum having the lowest amount of sensory and sympathetic nerve fibers (Fig. 2C). Interestingly, when comparing the density of CGRP and TH in the three age groups, the young animals had a significantly lower density ($p < 0.05$) of CGRP+ ($2261 \pm 442 \text{ mm/mm}^3$) and TH+ ($995 \pm 200 \text{ mm/mm}^3$) nerve fibers compared to adult (CGRP+: $3723 \pm 474 \text{ mm/mm}^3$; TH+: $2796 \pm 416 \text{ mm/mm}^3$) and aging (CGRP+: $3574 \pm 310 \text{ mm/mm}^3$; TH+: $3750 \pm 260 \text{ mm/mm}^3$) animals. This seemingly contradictory finding can be explained by noting that the thickness of the periosteum shrinks with age with relative thickness of young, adult and aging cambium layer being 12:4:1, respectively.

Similar to other studies, we show that the sensory and sympathetic nerve fibers in the periosteum have distinctive morphologies. TH+ sympathetic fibers have a “corkscrew” morphology and are typically found wrapping around blood vessels in the outer cambium layer which is adjacent to the outer fibrous layer (Fig. 2A,B). On the other hand, CGRP+ sensory fibers display a more linear pattern along the long axis of the femur and are usually found immediately adjacent to cortical bone within the cambium layer (Fig. 2A–C). Furthermore, we observed that both sensory and sympathetic nerve fibers predominately innervated the cambium layer versus the fibrous layer (data not included).
A combination of confocal and bright field microscopy was used to characterize the sensory and sympathetic innervation of cortical bone in young, adult and aging femurs (Fig. 3). CGRP+ sensory and TH+ sympathetic fibers were exclusively observed in Haversian canals. Haversian canals were not noted in young animals, as the largely cartilaginous bone had yet to form canals, which are an indication of the formation of mature, compact bone. Not all Haversian canals were vascularized (i.e., contained CD31+ blood vessels) and significantly more (p < 0.05) canals were vascularized in the adult femur compared to aging animals, 89 ± 3% versus 62 ± 3%, respectively.

Similar to the periosteum and bone marrow, TH+ sympathetic fibers in cortical bone had a cylindrical morphology and wrapped around CD31+ endothelial vessels. CGRP+ sensory fibers were also found in the canals, in close proximity to blood vessels and had a linear appearance. Approximately 26% of all Haversian canals were innervated by CGRP+ nerve fibers in both the adult and aging cortical bone (Fig. 3B,C). Interestingly, we observed a significant decline in the percentage of canals innervated by TH+ sympathetic fibers, 48 ± 5% versus 14 ± 2% in the adult and aging animal, respectively (Fig. 3E,F). As previously stated, no Haversian canals were found in young cortical bone though we did observe occasional lone sensory (Fig. 3A) and sympathetic (Fig. 3D) nerve fiber innervation of this bone compartment at this age. It should be noted that we did observe a significant difference (p < 0.05) in the percentage of canals in the adult (8 ± 1%) and aging (3 ± 1%) that had either CGRP+ and/or TH+ nerve fibers but did not contain CD31+ blood vessels.

CGRP+ sensory and TH+ sympathetic innervation of the bone marrow

In the bone marrow of the young, adult and aging femur CGRP+ sensory nerve fibers exhibited a relatively linear morphology in the marrow of all examined age

---

**Fig. 3.** Blood vessels, sensory and sympathetic nerve fibers that innervate the cortical bone in the young, adult and aging femur. In these images, the cortical bone (CB) is imaged by differential interfere contrast (DIC) and nuclei within the cortical bone are stained by DAPI (blue). In the young animal, the CB is largely cartilaginous with some woven bone and there are not any well-formed Haversian canals (HC) or CD31+ blood vessels although occasional CGRP+ sensory fibers (A) and TH+ sympathetic (D) nerve fibers can be observed. With aging, both the adult (B, E) and aging (C, F) cortical bone of the femur becomes mineralized and nearly all sensory or sympathetic nerve fibers in the adult and aging cortical bone are present in Haversian canals most of which are vascularized by CD31+ blood vessels. With age, the number of CD31+ Haversian canals declines, as does the percent of CD31+ Haversian canals that contain TH+ sympathetic nerve fibers. A similar decline was not observed in the percent of CD31+ Haversian canals innervated by CGRP+ sensory nerve fibers. It should be noted that we did not observe any sensory or sympathetic nerve fibers in the young, adult or aging subchondral bone. All confocal images are composed of 2 serially adjacent 60 micron sections = total z-stack of 120 microns.
groups (Fig. 4A–C). The young bone marrow (576 ± 39 mm/mm³) had a slightly higher CGRP+ sensory nerve density/unit area compared to the adult (344 ± 7 mm/m m²) and aging (343 ± 16 mm/mm³) bone marrow, but both these differences were not statistically significant. High power images of CGRP+ sensory structures in the marrow revealed their branching patterns (Fig. 4D–F) which was seen in all aspects of the bone marrow. TH+ sympathetic fibers in the marrow demonstrated a distinctive cylindrical morphology (Fig. 4G–I) and although there was a small increase in TH+ sympathetic nerve fiber density/unit area with age (young: 376 ± 48 mm/mm³; adult: 461 ± 53 mm/mm³; aging: 518 ± 52 mm/mm³) these differences were not statistically significant.

Immunohistochemical staining of nerve fibers in non-decalcified and decalcified bone

The decalcification of calcified bone requires using chemicals like EDTA before the bone is processed for immunohistochemistry. However, few studies have investigated the effects of these chemicals on the retention of neurologic markers post-decalcification. CGRP+ sensory fibers and tropomyosin-related kinase receptor A+ (TrkA), the cognate receptor of NGF, were examined in the marrow and periosteum of young non-decalcified and decalcified femurs (Fig. 5). We selected young tissue because at this stage of development, the femur is only partially mineralized allowing for easy sectioning of the femur without decalcification. CGRP immunostaining was robust in both tissue compartments regardless of whether the tissue had undergone decalcification (Fig. 5A,B). However, the decalcification process negatively affected the robustness of TrkA immunostaining in both the periosteum and bone marrow (Fig. 5C,D). In addition to the CGRP and TrkA neuronal markers, we examined the effects of decalcification on various other neuronal markers (Table 2). What is interesting is that the negative effects of decalcification were antigen specific, in that some markers like CGRP, TH and CD31 were unaffected by the decalcification process while others like TrkA, p75 and NGF were significantly affected by the process (Table 2).

DISCUSSION

Changes in the sensory and sympathetic innervation of the skeleton across the lifespan

In examining the femur of young, adult and aging mice, it is clear that remarkable changes occur in both the bone and cartilage over the lifespan (Manolagas and Parfitt, 2010). The most obvious change is simply the size of the femur as the young 10-day-old mouse femur is approximately 1/4 the length of the adult or aging femur. A second major change is in the extent of bone calcification, as the cortical wall of the young femur is almost completely cartilaginous and non-calcified whereas the adult and aging cortical bone is highly calcified. A third major change is the age-related decline in the thickness of the cambium layer of the periosteum which is accompanied by a concomitant reduction in the proliferation of osteoprogenitor cells (Thompson et al., 2016). In the young mouse femur, the cambium layer of the periosteum is 56 microns thick, in the adult it is 20 microns thick and in the aging mouse it is 6 microns thick. Similar age-related decline in the thickness of the periosteum have been observed in the rabbit and human bone (O’Driscoill et al., 2001; Seeman, 2003; Allen et al., 2004). Other changes that are evident when comparing the adult vs. the aging femur are that compared to the adult, in the aging femur; the cortical wall becomes thinner, trabeculae are fewer in number, the marrow has many more adipose deposits, and the articular cartilage of the knee becomes thinner and more calcified (Exton-Smith et al., 1969; Firooznia et al., 1984; Ferguson et al., 2003; Manolagas and Parfitt, 2010).

Considering the number of changes that occur in bone and articular cartilage over the lifespan, one might expect a dramatic decline in the sensory and sympathetic innervation of the femur. However, while there clearly is a marked decline in the overall number of sensory and sympathetic nerve fibers in the periosteum and sympathetic nerves in cortical bone with aging, the general morphology and organization of the nerves remains remarkably similar. Thus, although the cambium layer of the periosteum undergoes a 10-fold decrease in thickness with age with a clear loss in the overall number of sensory and sympathetic nerve fibers, the general organization remains the same with there being CD31+ blood vessels, CGRP+ sensory nerve fibers and TH+ sympathetic fibers in the cambium layer, even in the greatly thinned aging periosteum. Similarly, in comparing the adult vs. aging cortical bone, while there is a decline in the percent of CD31+ Haversian canals that contain blood vessels (89% vs. 62%) the percent of CD31+ Haversian canals that are innervated by CGRP+ sensory fibers do not decline whereas there is a marked decline in CD31+ Haversian canals that are innervated by TH+ sympathetic nerve fibers with age. Interestingly, in the cortical wall of the young femur (which is largely cartilaginous, avascular and has no CD31+ endothelial cells as the Haversian canals have yet to form) one still finds occasional CGRP+ and TH+ nerve fibers in this structure. Similarly, although the presence of adipose deposits in the bone marrow is much more prevalent in the aging vs. the young or adult femur (Ferguson et al., 2003), there is not a significant difference in the density of innervation by CGRP+ and TH+ nerve fibers in the bone marrow when comparing the young, adult and aging femur. Lastly, no sensory fibers, sympathetic fibers, or CD31+ blood vessels were ever detected in the articular cartilage of the knee joint in the young, adult or aging femur.

Mechanisms that drive skeletal pain across the lifespan

The present findings suggest that sensory nerve fibers that are involved in detecting noxious stimuli in the skeleton are present across the lifespan of the animal. In light of this observation, a major question is whether
Fig. 4. Sensory fibers, sympathetic fibers and blood vessels in the bone marrow of the young, adult and aging mouse femur. In these images, the sympathetic nerve fibers (yellow) are labeled by an antibody raised against tyrosine hydroxylase (TH), the sensory nerve fibers (green) are labeled with an antibody raised against calcitonin gene-related peptide (CGRP) and the endothelial cells are labeled with an antibody raised against 140 kD glycoprotein known as platelet endothelial cell adhesion molecule which is also known as CD31 (red). Note that the TH+ sympathetic fibers in the bone marrow have a characteristic “corkscrew shaped” appearance (A–C, G–I) as they are tightly wrapped around blood vessels. In contrast, CGRP+ sensory nerve fibers have a much more linear appearance (D–F) and do not have the same intimate association with blood vessels (A–C). Also, note that there is not a significant decline in either the density of the sensory or sympathetic nerve fibers innervation of the bone marrow with age, although sensory nerve fibers do appear to have more branch points with age and the intensity of TH immunoreactivity in the sympathetic fibers appears to decline with age (i.e., compare Figs. G vs. H or I). Confocal images in A, B and C were obtained from two serially adjacent tissue sections. The first 30 micron serial section was stained for TH, CD31, and DAPI. The second 30 micron serial section was stained for CGRP, CD31, and DAPI. These two 30 micron sections were then aligned and stacked on top of each other to generate the 60 micron Z-stack shown in A–C. This figure shows the relationship of CGRP+ sensory, TH+ sympathetic, and CD31+ blood vessels in the young, adult and aging bone marrow, respectively. As one can see in all of these images, the TH+ sympathetic nerve fibers have a distinct morphology and closer relationship to CD31+ blood vessels as compared to the CGRP+ sensory nerve fibers. In (D–F) single 60 micron sections were stained for CGRP and DAPI and in G, H, and I single 60 micron sections were stained with TH and DAPI.
similar peripheral mechanisms drive skeletal pain in the young, adult and aging skeleton? While in many ways this is a difficult question to address, as pain is a subjective experience, a variety of clinical studies have suggested that many therapies that are effective in relieving skeletal pain in the adult or aging animal may be effective at relieving skeletal pain in the young. One of the best examples of this are the bisphosphonates and Denosumab which were originally shown to reduce bone cancer in adults by inhibition of osteoclast induced acidosis. More recently, it has been shown that bisphosphonates or Denosumab can also markedly attenuate skeletal pain in neonatal and pediatric patients with osteogenesis imperfecta, juvenile Paget’s disease, fibrous dysplasia, and aneurysmal bone cyst (Boyce, 2017). Mechanistically this makes sense as the present study clearly shows that there are many CGRP + sensory fibers innervating the young, adult and aging bone. Previous work has shown that many CGRP + fibers also express acid sensing ion channels such as TRPV1, ASIC-1 and ASIC-3 (Gajda et al., 2005; Mantyh, 2014) and these ion channels are known to be activated by the extracellular pH of 4 that is generated by osteoclasts. These data suggest that if excessive osteoclast induced acidosis is present, whether it be in young, adult or aging patients, blocking this acidosis can attenuate skeletal pain.

A second common mechanism which probably drives pain in the young, adult and aged skeleton is stimulation of mechanosensitive nociceptors that innervate the periosteum, cortical bone and bone marrow. Previous studies have shown that many of the sensory nerve fibers that innervate the periosteum and cortical bone are mechanosensitive nociceptors that rapidly respond to mechanical distortion of either the periosteum and/or the underlying cortical bone (Inman et al., 1944; Sakada and Taguchi, 1971; Mahns et al., 2006; Zhao and Levy, 2014; Nencini and Ivanusic, 2016). Similarly, increased intraosseous pressure in the bone marrow will stimulate mechanosensitive nociceptors that innervate the bone marrow (Furusawa, 1970; Seike, 1976; Haegerstam, 2001; Nencini and Ivanusic, 2017). As many genetic diseases involving bone and cartilage result in relatively weak bone, normal loading of a weakened bone would be expected to result in pain due to distortion of the mechanosensitive sensory nerve fibers that densely innervate the young, adult and aging bone.

A third mechanism that appears to drive skeletal pain in the young, adult and aging bone and joint, is the release of inflammatory mediators that occurs in disease or following injury of bone and/or cartilage. Several mediators including prostaglandins, bradykinin, endothelins, and nerve growth factor (Mantyh, 2014, Nencini and Ivanusic, 2016, Nencini et al., 2017) all have been shown to excite and/or sensitize nociceptors that innervate the skeleton. Therapies targeting these mediators have been shown to relieve pain in a variety of human skeletal pathologies or diseases, including osteoarthritis (Schnitzer et al., 2011; Seidel and Lane, 2012; Seidel

Table 2. The qualitative assessment of the impact that the decalcification process has on the ability to immunohistochemically detect neuronal and vascular antigens in the mouse femur. Note that several antigens are negatively affected by the decalcification process and of the 6 antigens presented here, only CGRP, TH, and CD31 showed little or no decline in immunoreactivity when comparing young non-decalcified vs. decalcified femur. These results suggest that using a positive control such as the young femur (which is largely cartilaginous and can be sectioned with or without decalcification) is essential when comparing young, adult and aging bone as the extent and length of the decalcification process may impact the ability to detect an antigen of interest.

| Antigen | Non-decalcified Young Marrow | Decalcified Young Marrow | Decalcified Adult Marrow | Decalcified Aging Marrow |
|---------|------------------------------|--------------------------|--------------------------|--------------------------|
| CGRP   | +++                          | +                        | +                        | +                        |
| TH     | +++                          | +                        | +                        | +                        |
| CD31   | +++                          | +                        | +                        | +                        |
| p75    | +++                          | +                        | —                        | —                        |
| NGF    | +++                          | +                        | —                        | —                        |
| TrkA   | +++                          | +                        | —                        | +                        |
et al., 2013; Tiseo et al., 2014), low back pain (Katz et al., 2011; Kivitz et al., 2013), and bone cancer pain (Sopata et al., 2015, Majuta et al., In Press). Presumably, blockade of NGF will be contraindicated in young patients with skeletal pain as NGF is involved in the growth and survival of the developing sensory and sympathetic nervous system in the young. However, many individuals with genetic disorders of the bone and joint (such as fibrous dysplasia) not only have significant pain when they are young but continue to have chronic skeletal pain throughout their adult life (Chapurlat et al., 2012). Whether targeting blockade of NGF or its cognate receptor TrkA will block pain in adults with genetic disorders of the bone and joints has yet to be determined.

The fourth mechanism that may be involved in driving skeletal pain is ectopic nerve sprouting. Following injury or disease, several neurotrophic factors including NGF are released by stromal and inflammatory cells and can induce an exuberant and highly ectopic sprouting resulting in hyper-innervation of the marrow, mineralized bone and periosteum (Mantyh, 2014). Importantly, NGF not only induces ectopic nerve sprouting into areas of bone that are normally poorly innervated, but also sensitizes TrkA+ nociceptors (Woolf et al., 1994, Dyck et al., 1997; Ma and Woolf, 1997; Ueda et al., 2002; Svensson et al., 2003; Pezet and McMahon, 2006; Rukwied et al., 2010, Nencini et al., 2017) so that even normally non-noxious loading or movement of the bone is perceived as a highly noxious event. Skeletal diseases where ectopic sprouting has been observed are bone cancer (Jimenez-Andrade et al., 2010, Mantyh et al., 2010; Bloom et al., 2011), unhealed bone fractures (Hukkanen et al., 1992, Chartier et al., 2014), osteoarthritis (Walsh et al., 2010; Jimenez-Andrade and Mantyh, 2012; Driscoll et al., 2016), and the degenerated vertebral disc (Johnson et al., 2002, 2005; Tolofari et al., 2010). Once this ectopic nerve sprouting has occurred, mechanical strain and/or distortion of a weakened bone or joint may result in normally innocuous movement and loading of the bone now being perceived as a noxious event. Whether significant and unwanted sprouting of sensory and sympathetic nerve fibers also occurs in young patients with genetic disorders of the skeleton has yet to be determined, but if it does occur, it may provide insight into the mechanisms that drive the transition from acute to chronic skeletal pain in these patients (Holley et al., 2017).

The normally highly restricted innervation of the young, adult and aging femur may change following injury or disease

Two of the most remarkable aspects of the present study are just how richly innervated the young bone is and how restricted and regulated the location, density and morphology of sensory and sympathetic nerve fibers is throughout the lifespan. Thus, across the lifespan, the areas of bone and joint with the highest density of sensory and sympathetic nerve fibers remains the same: periosteum > marrow > cortical bone > articular cartilage. Even within each compartment of bone there is tight regulation in terms of density, phenotype and morphology such that in the periosteum > 90% of nerve fibers are in the cambium, with fewer than 10% being present in the fibrous layer. In adult and aging cortical bone the great majority of sensory and sympathetic nerve fibers are only found in vascularized CD31+ Haversian canals. In the bone marrow, the sensory nerve fibers are linear in appearance, whereas the sympathetic nerve fibers nearly always have a "corkscrew" shaped pattern and tightly wrap around CD31+ blood vessels.

Currently, we know relatively little about the specific molecules and mechanisms that coordinate the growth, sprouting and maintenance of sensory and sympathetic nerve fibers in bone and cartilage (Ivanusic, 2009, Jimenez-Andrade et al., 2010, Asano et al., 2014; Nencini et al., 2017). Molecules that have been implicated in regulating these processes include NGF and members of the netrin, semaphorin, integrin, FGF and VEGF family (Voyvodic, 1987; Graef et al., 2003, Jimenez-Andrade et al., 2010; Bloom et al., 2011; Ascano et al., 2012; Krock et al., 2014; Selvaraj et al., 2015; Kuner and Flor, 2016, Nencini et al., 2017). However, what specific cell types synthesize and release these growth factors, how the expression of these factors changes due to injury, disease or aging, and whether the phenotype and response characteristics of sensory and sympathetic nerve fibers that innervate the skeleton change across the lifespan remains largely unknown. Understanding the interplay between bone cells and nerves across the lifespan may provide insights into how nerves participate in driving age-related changes in bone and cartilage (Elefteriou et al., 2014) and how changes in bone and cartilage drive skeletal pain across the lifespan.

Conclusions and limitations

The present study suggests that the young, adult and aging mouse femur, the periosteum, cortical bone and bone marrow are all innervated by sensory and sympathetic nerve fibers. The compartments of bone that had the highest density of nerve fibers/unit area remained the same in the young, adult and aging femur (i.e., periosteum > marrow > cortical bone) with no nerve fibers being observed in the articular cartilage at any age. These results suggest while there is a significant decline in both sensory and sympathetic innervation of the skeleton with age, the anatomical substrates required for detection of noxious stimuli and the efferent modulation of bone and joint are present in the young, adult and aging skeleton. Limitations of the study are that the analysis was only performed on the normal male mouse femur and only antigens that showed little loss of antigenicity following decalcification were examined.

ACKNOWLEDGMENTS

This research was supported by the National Institutes of Health (grant numbers CA154550, CA157449, and NS023970) to Patrick Mantyh. Dr. Mantyh has served as a consultant and/or received research grants from Abbott (Abbott Park, IL), Adolor (Exton, PA), Array
San Francisco, CA), and Roche (Palo Alto, CA). All other authors report no conflict of interest.

REFERENCES

Allen MR, Hock JM, Burr DB (2004) Periosteum: biology, regulation, and response to osteoporosis therapies. Bone 35(5):1003–1012.

Arnold W (1988) Immunohistochemical investigation of the human inner ear. Limitations and prospects. Acta Otolaryngol 105(5–6):392–397.

Ascano M, Bodmer D, Kuruvilla R (2012) Endocytic trafficking of neurotrophins in neural development. Trends Cell Biol 22(5):266–273.

Aso K, Ikeuchi M, Izumi M, Sugimura N, Kato T, Ushida T, Tani T (2014) Nociceptive phenotype of dorsal root ganglia neurons innervating the subchondral bone in rat knee joints. Eur J Pain 18(2):174–181.

Bloom AP, Jimenez-Andrade JM, Taylor RN, Castaneda-Corral G, Kaczmarska MJ, Freeman KT, Coughlin KA, Ghilardi JR, Kuskowski MA, Mantyh PW (2011) Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J Pain 12(6):698–711.

Boyle AM (2017) Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep 15(4):283–292.

Boyle AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, Bassim C, Cherman N, Ellsworth M, Kasa-Vubu JZ, Farley FA, Molinolo AA, Bhattacharyya N, Collins MT (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 27(2):1462–1470.

Brandi ML, Collin-Osdoby P (2006) Vascular biology and the skeleton. J Bone Miner Res 21(2):183–192.

Charpaut RD, Gensburger D, Jimenez-Andrade JM, Ghilardi JR, Kelly M, Mantyh P (2012) Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. Orphanet J Rare Dis 7(Suppl 1):S3.

Chartier SR, Thompson ML, Longo G, Fealk MN, Majuta LA, Mantyh PW (2014) Exuberant sprouting of sensory and sympathetic nerve fibers in nonhealed bone fractures and the generation and maintenance of chronic skeletal pain. Pain 155(11):2323–2336.

Chawla S, Henshaw R, Seeger L, Choy E, Blay JF, Ferron SI, Koepp J, Grimer R, Reichardt P, Rutfowski P, Schuetze S, Skubitz K, Siddon A, Thomas D, Ghan Y, Jacobs I (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 14(10):901–908.

Clinch J, Eccleston C (2009) Chronic musculoskeletal pain in children: assessment and management. Rheumatology, kep001.

Dissociation of bone pain problems and response to PCN. Bone 33(3):387–398.

Firooznia H, Golimbu C, Rafi M, Schwartz MS, Alterman ER (1984) Quantitative computed tomography assessment of spinal trabecular bone. II. In osteoporotic women with and without vertebral fractures. J Comput Tomogr 8(2):99–103.

Freeman KT, Koewler NJ, Jimenez-Andrade JM, Buus RJ, Herrera MB, Martin CD, Ghilardi JR, Kuskowski MA, Mantyh PW (2008) A fracture pain model in the rat: adaptation of a closed femur fracture model to study skeletal pain. Anesthesiology 108(3):473–483.

Furusawa S (1970) A neurophysiological study on the sensibility of the bone marrow. Nihon Seikeigeka Gakkai Zasshi 44(5):365–370.

Gajda M, Litwin JA, Cichocki T, Timmernans JP, Adriaensen D (2005) Development of sensory innervation in rat tibia: co-localization of CGRP and substance P with growth-associated protein 43 (GAP-43). J Anat 207(2):135–144.

Gedde N, Hilgers MV, Polak JM, Weaver C (2013) Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer 60(6):1078–1080.

Graef IA, Wang F, Charron F, Chen L, Neilson J, Tessier-Lavigne M, Crabtree GR (2003) Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. Cell 113(5):657–670.

Grasemann C, Schuendeln MM, Hovel M, Schweiger B, Bergmann C, Herrmann R, Wiczer-Kroll P, Tabel B, Wieland R, Hauffa BP (2013) Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s disease. J Clin Endocrinol Metab 98(8):3121–3126.

Haeagerstam GA (2001) Pathophysiology of bone pain: a review. Acta Orthop Scand 72(3):308–317.

Hayat M. (2002). Factors affecting antigen retrieval. Microscopy, immunohistochemistry, and antigen retrieval methods: for light and electron microscopy. 71-93.

Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, Weaver C (2000) Peak bone mass. Osteoporos Int 11(12):985–1009.

Holley AL, Wilson AC, Palermo TM (2017) Predictors of the transition from acute to persistent musculoskeletal pain in children and adolescents: a prospective study. Pain 158(5):794–801.

Hoyer-Kuhn H, Seimler O, Schoenau E (2014) Effect of denosumab on bone growth in osteogenesis imperfecta. J Clin Endocrinol Metab 99(11):3954–3959.

Hukkanen M, Konttinen YT, Rees RG, Santavirta S, Terenghi G, Polak JM (1992) Distribution of nerve endings and sensory neuromasts in rat synovium, meniscus and bone. Int J Tissue React 14(1):1–10.

Hukkanen M, Konttinen YT, Santavirta S, Paavolainen P, Xu H, Terenghi G, Polak JM (1993) Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neural involvement in bone growth and remodelling. Neuroscience 54(4):369–379.

Inman VT, John B, Saunders deC M (1944) Referred pain from acute to persistent musculoskeletal pain in children and adolescents: a prospective study. Pain 158(5):794–801.

Ivanusic JJ (2009) Size, neurochemistry, and segmental distribution of sensory neurons innervating the rat tibia. J Comp Neurol 517(3):276–283.

Jimenez-Andrade JM, Bloom AP, Mantyh WG, Koewler NJ, Freeman KT, Delong D, Ghilardi JR, Kuskowski MA, Mantyh PW (2009) Capsaicin-sensitive sensory nerve fibers contribute to the generation and maintenance of skeletal fracture pain. Neuroscience 162(4):1244–1254.

Jimenez-Andrade JM, Bloom AP, Stake JI, Mantyh PW, Taylor RN, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW (2010) Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci 30(44):14649–14656.

Jimenez-Andrade JM, Mantyh PW (2012) Sensory and sympathetic nerve fibers undergo sprouting and neurona formation in the painful arthritic joint of geriatric mice. Arthritis Res Ther 14(3):R101.
Seike W (1976) Electrophysiological and histological studies on the sensibility of the bone marrow nerve terminal. Yonago Acta Med 20(3):192–211.

Selvaraj D, Gangadharan V, Michalski CW, Kurejova M, Stosser S, Srivastava K, Schweizerhof M, Wallenberger J, Ferrara N, Heppenstall P, Shibuya M, Augustin HG, Kuner R (2015) A functional role for VEGFR1 expressed in peripheral sensory neurons in cancer pain. Cancer Cell 27(6):780–796.

Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E (2012) First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 12(3):183–188.

Shi SR, Key ME, Kalra KL (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39(6):741–748.

Sopata M, Katz N, Carey W, Smith MD, Keller D, Verburg KM, West CR, Wolfam G, Brown MT (2015) Efficacy and safety of tanezumab in the treatment of pain from bone metastases. Pain 156(9):1703–1713.

Svensson P, Cairms BE, Wang K, Arendt-Nielsen L (2003) Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain 104(1– 2):241–247.

Thompson ML, Chartier SR, Mitchell SA, Mantyh PW (2016) Preventing painful age-related bone fractures: anti-sclerostin therapy builds cortical bone and increases the proliferation of osteogenic cells in the periosteum of the geriatric mouse femur. Mol Pain 12.

Tiseo PJ, Kivitz AJ, Ervin JE, Ren H, Mellis SJ (2014) Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain 155(7):1245–1252.

Tolofari SK, Richardson SM, Freemont AJ, Hoyland JA (2010) Expression of semaphorin 3A and its receptors in the human intervertebral disc: potential role in regulating neural ingrowth in the degenerate intervertebral disc. Arthritis Res Ther 12(1):R1.

Ueda M, Hirose M, Takei N, Ibuki T, Naruse Y, Amaya F, Ibata Y, Tanaka M (2002) Nerve growth factor induces systemic hyperalgesia after thoracic burn injury in the rat. Neurosci Lett 328(2):97–100.

Voyvodic JT (1987) Development and regulation of dendrites in the rat superior cervical ganglion. J Neurosci 7(3):904–912.

Walsh DA, McWilliams DF, Turley MJ, Dixon MR, Franses RE, Mapp PI, Wilson D (2010) Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 49(10):1852–1861.

Ward L, Bardai G, Moffatt P, Al-Jallad H, Trejo P, Glibert FH, Rauch F (2016) Osteogenesis imperfecta type VI in individuals from Northern Canada. Calcif Tissue Int 98(6):566–572.

Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81(9):646–656.

Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J (1994) Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62(2):327–331.

Zhao J, Levy D (2014) The sensory innervation of the calvarial periosteum is nociceptive and contributes to headache-like behavior. Pain 155(7):1392–1400.

(Received 24 August 2017, Accepted 23 January 2018) (Available online 10 February 2018)